Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jun;31(6):1189-1192.
doi: 10.3201/eid3106.241519.

Cadaveric Human Growth Hormone-Associated Creutzfeldt-Jakob Disease with Long Latency Period, United States

Case Reports

Cadaveric Human Growth Hormone-Associated Creutzfeldt-Jakob Disease with Long Latency Period, United States

Anatevka S Ribeiro et al. Emerg Infect Dis. 2025 Jun.

Abstract

We report a case of iatrogenic Creutzfeldt-Jakob disease (iCJD) after a 48.3-year incubation period in a patient treated with cadaveric human growth hormone. iCJD was pathologically confirmed; genetic analysis was negative for pathogenic mutations. Clinicians should consider iCJD in patients with progressive neurologic signs who had received cadaveric human growth hormone treatment.

Keywords: CJD; Creutzfeldt-Jakob disease; PrPSc proteins; United States; human growth hormone; myoclonus; prions and related diseases; sporadic.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Magnetic resonance imaging of the brain from a case of cadaveric human growth hormone–associated Creutzfeldt-Jakob disease with long latency period, United States. A, B) Images obtained at initial clinical examination were unremarkable. C, D) Images obtained 3 months later demonstrated subtle areas of symmetric T2 hyperintensity in the insulae and frontotemporal lobes (C) and deep gray structures with diffusion restriction along the bilateral insulae and caudate heads without gadolinium enhancement (D).
Figure 2
Figure 2
Comparison of latency estimates among US cases in a study of chGH-associated CJD with long latency period, United States. The patient in this report (current CJD case) was treated with chGH for 9.3 years starting in late 1971 at 7 years of age, and neurologic symptoms developed when she was 58 years of age. We used data from all 36 US cases of chGH-associated CJD to compare estimates of CJD latency periods via 4 methods: first dose of chGH to symptom onset (red), midpoint of chGH treatment to symptom onset (green), last dose of chGH to symptom (blue), and midpoint of pre-1978 chGH to symptom onset (purple). Using those 4 methods, we believe the last (purple box plot) to be the most accurate, giving a best estimate of 48.3 years for our patient’s latency period. Black dots indicate other CJD cases, box top and bottoms indicate 25th and 75th percentiles, horizontal lines inside boxes indicate medians, and whiskers extend to the furthest observed points within 1.5 times the interquartile range from the 25th and 75th percentiles. chGH, cadaveric human growth hormone; CJD, Creutzfeldt-Jakob disease.

References

    1. Watson N, Brandel JP, Green A, Hermann P, Ladogana A, Lindsay T, et al. The importance of ongoing international surveillance for Creutzfeldt-Jakob disease. Nat Rev Neurol. 2021;17:362–79. 10.1038/s41582-021-00488-7 - DOI - PMC - PubMed
    1. Appleby BS, Shetty S, Elkasaby M. Genetic aspects of human prion diseases. Front Neurol. 2022;13:1003056. 10.3389/fneur.2022.1003056 - DOI - PMC - PubMed
    1. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. National Hormone & Pituitary Program (NHPP): information for people treated with pituitary human growth hormone [cited 2024 Jul 28]. https://www.niddk.nih.gov/health-information/endocrine-diseases/national...
    1. Brandel JP, Preece M, Brown P, Croes E, Laplanche JL, Agid Y, et al. Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet. 2003;362:128–30. 10.1016/S0140-6736(03)13867-6 - DOI - PubMed
    1. Douet JY, Huor A, Cassard H, Lugan S, Aron N, Mesic C, et al. Prion strains associated with iatrogenic CJD in French and UK human growth hormone recipients. Acta Neuropathol Commun. 2021;9:145. 10.1186/s40478-021-01247-x - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources